• Mashup Score: 1

    Progress depends on fully engaging people and communities in improving health and care With a general election in prospect, and opinion polls showing the Labour Party well ahead of the Conservatives, attention is turning to Labour’s plans for health and social care. In his speech last week, Labour’s shadow health secretary, Wes Streeting, reiterated his party’s mission as “to get the NHS back on its feet and fit for the future.”1 He acknowledged that achieving this mission would take time, investment, and reform, adding that reform is more important than investment. He might have added, but didn’t, that time is even more important. More specifically, Streeting identified three shifts that are needed: from hospital to community, from analogue to digital, and from sickness to prevention. He also emphasised that there is no solution to the crisis in the NHS that doesn’t include a plan for social care, promising to deliver a 10 year plan for health and social care. Notably absent from the

    Tweet Tweets with this article
    • Implementing @UKLabour ’s @NHSEngland plans requires leaders to think and act creatively https://t.co/WlaUuUfaab via @profchrisham

  • Mashup Score: 0

    Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the survival rate of children with ALL. In the past two decades, the use of minimal (measurable) residual disease (MRD) measurements early in therapy improved risk group stratification with subsequent treatment intensifications for patients at high risk of relapse, and enabled a reduction of treatment for low-risk patients. The recent development of more sensitive MRD technologies may further affect risk stratification. Molecular genetic profiling has led to the discovery of many new subtypes and their driver genetic alterations. This increased our understanding of the biological basis of ALL, improved risk classification, and enabled implementation of precision medicine. In the past decade, immunotherapies, including bispecific antibodies, antibody-drug conjugates, and cellular therapies directed against surface proteins, led to more effective and less toxic therapies, replacing intensive chemotherapy co

    Tweet Tweets with this article
    • Great review in @JCO_ASCO on how integration of molecular & immunotherapeutic testing platforms have the potential to produce a universal cure for pediatric ALL. We must work to make these technologies available to all. #ChildhoodCancer #pedcsm https://t.co/z6OYlikkjF

  • Mashup Score: 1

    Patients dealing with cancers that have resisted immuno-oncology (IO) therapies potentially have a new treatment option on the horizon. More than a decade after the first checkpoint inhibitor raised hopes, next-generation investigational IO is lighting up clinics with long-sought encouraging results against the persistent “cold” tumors involved in colorectal, lung,

    Tweet Tweets with this article
    • 21 minutes to go! Starting at 1 pm EST. Link to register and join the webinar @endpts. https://t.co/XtkoxJNPAw https://t.co/zbA9ot3iMN https://t.co/TztquyHp6R

  • Mashup Score: 1

    In the article that accompanies this editorial, Leypoldt et al 1 describe the results of a forward-thinking study focused on the management of high-risk newly diagnosed multiple myeloma (HR NDMM) using the quadruplet (quad) regimen: isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd). This multicenter, phase II trial enrolled patients with HR NDMM, cytogenetically defined as the presence of del17p, t(4;14), t(14;16), or more than three copies of 1q21. Patients were not eligible if they had

    Tweet Tweets with this article
    • 👏Excellent Editorial in @JCO_ASCO by @AjayNookaMD @JKaufmanMD and @SagarLonialMD on the GMMG-CONCEPT trial for High Risk Myeloma #mmsm Glücksklee, the Quad, and High-Risk Myeloma https://t.co/H4UvCkUAjn